scholarly journals Scalp Psoriasis and Biologic Agents: A Review

2021 ◽  
pp. 1-10
Author(s):  
Ilias Papadimitriou ◽  
Katerina Bakirtzi ◽  
Alexander Katoulis ◽  
Dimitrios Ioannides
Keyword(s):  
Quality Of Life ◽  
Plaque Psoriasis ◽  
Psychological Impact ◽  
Life Quality ◽  
Severity Index ◽  
Scalp Psoriasis ◽  
Significant Regression ◽  
Term Maintenance

Scalp-localized psoriasis is common among patients affected with plaque psoriasis, rendering its treatment exceedingly difficult. Furthermore, the symptoms caused by the disease like scaling, erythema, and pruritus, among others, pose a major psychological impact and a significant regression in the quality of life of the affected patients. Biologics have proved their efficacy in assuaging the symptoms, in terms of Psoriasis Area and Severity Index (PASI) reduction, and offering optimum quality of life, by decreasing the Dermatology Life Quality Index (DLQI) in the patients suffering from plaque psoriasis. Herein, we sought to evaluate the efficacy of biologics and small molecules in controlling the symptoms and their ability to offer long-term maintenance in the disease activity.

Psoriatic Nail Disease: Quality of Life and Treatment

2009 ◽  
Vol 13 (5_suppl) ◽  
pp. S102-S106 ◽  
Author(s):  
Aditya K. Gupta ◽  
Elizabeth A. Cooper
Keyword(s):  
Quality Of Life ◽  
Psoriatic Arthritis ◽  
Plaque Psoriasis ◽  
Large Scale ◽  
Severity Index ◽  
Biologic Therapies ◽  
Nail Psoriasis ◽  
Psoriatic Nail Disease

Nail psoriasis is common among patients with plaque psoriasis or psoriatic arthritis and has a detrimental effect on quality of life. However, there are currently no standardized therapeutic regimens for nail psoriasis. Traditional treatments for nail psoriasis, which include topical, intralesional, and oral therapies, may be time-consuming, painful, or unsafe when administered long term. Biologic therapies have demonstrated efficacy for plaque psoriasis and psoriatic arthritis; these therapies may be particularly promising for the treatment of nail psoriasis as both groups of patients have an elevated incidence of nail dystrophy. The biologic therapies adalimumab, alefacept, efalizumab, etanercept, and infliximab have demonstrated clinically important nail psoriasis improvements using the Nail Psoriasis Severity Index, a helpful tool that, upon validation, will allow comparison across treatments and trials. Large-scale, long-term trials using standardized outcome measures are needed to further evaluate biologic therapies for the treatment of nail psoriasis.

The Effect of Psoriasis on Patients' Quality of Life and Improvements Associated with Alefacept Therapy

2004 ◽  
Vol 8 (2_suppl) ◽  
pp. 20-25
Author(s):  
Alan Menter
Keyword(s):  
Quality Of Life ◽  
Unmet Need ◽  
Life Quality ◽  
Severity Index ◽  
Biologic Agent ◽  
Number Of Patients ◽  
Negative Effect ◽  
Clinical Measures

Patients with psoriasis may experience impaired psychosocial mental status regardless of their objectively defined disease severity. The objective clinical measures of disease that are commonly used to evaluate a patient's psoriasis fail to take into account the effect of psoriasis on patients' quality of life (QOL). As a result, a significant number of patients are dissatisfied with conventional treatments and are searching for new options. A high unmet need for effective and safe long-term therapies that can also improve patients' QOL exists in psoriasis. Alefacept, a selective biologic agent specifically designed for the treatment of psoriasis, provides improvement in both the physical (as measured by the Psoriasis Area and Severity Index) and mental (as measured by the Dermatology Life Quality Index) aspects of the disease. Additionally, alefacept is extremely well tolerated, with no negative effect on QOL, and the improvement in QOL is maintained off-treatment, which is consistent with its remittive effects on the disease. Alefacept helps fulfill the needs of psoriasis patients by providing efficacy, safety, off-treatment remissions, and improvement in QOL.

scholarly journals Reporting of Quality of Life in Clinical Trials of Biologics for Plaque Psoriasis: A Systematic Review

2018 ◽  
Vol 2 (5) ◽  
Author(s):  
Giselle Prado ◽  
Anna J Nichols ◽  
Mercedes Florez-White ◽  
Francisco Kerdel
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Clinical Trials ◽  
Plaque Psoriasis ◽  
Dermatology Life Quality Index ◽  
Quality Index ◽  
Life Quality ◽  
Risk Of Bias ◽  
The Mean

Background: Psoriasis is a chronic remitting and relapsing skin disease. For many patients, improved quality of life (QoL) is as important as clinical improvement of lesions.Objective: To review reporting of Dermatology Life Quality Index (DLQI) in randomized controlled trials (RCTs) of biologics for adult patients with plaque psoriasis.Methods: A systematic review was conducted in 4 databases for RCTs that measured DLQI at baseline and endpoint. A data collection form was created for collecting study variables. Risk of bias was assessed using the Cochrane risk of bias tool.Results: Thirty-four RCTs enrolling 16,784 patients were included. Complete baseline and final mean DLQI data was retrieved for 24 studies (70.6%). The mean DLQI at baseline was reported in 79.4% of RCTs. The median at baseline was reported in 14.7% of RCTs. The mean DLQI at endpoint was reported in 23.5% of RCTs and the median DLQI at endpoint was reported in 5.9% of RCTs. The mean change in DLQI was reported in 64.7% of RCTs.Conclusions: DLQI was measured in most clinical trials assessing the efficacy of biologics for psoriasis. Studies did not adhere to uniform standards in publishing results, making analysis of the impact on DLQI challenging.Key Words: plaque psoriasis, quality of life, Dermatology Life Quality Index, Systematic Review, biologic therapy

scholarly journals Surgical management of recurrent disc herniations with microdiscectomy and long-term results on life quality: Detailed analysis of 70 cases

2016 ◽  
Vol 7 (01) ◽  
pp. 87-90 ◽  
Author(s):  
Serdal Albayrak ◽  
Sait Ozturk ◽  
Emre Durdag ◽  
Ömer Ayden
Keyword(s):  
Quality Of Life ◽  
Facet Joint ◽  
Lumbar Disc ◽  
Life Quality ◽  
Early Period ◽  
Long Term Results ◽  
Disc Herniations

ABSTRACT Background: Aim of this paper is to recall the surgical technique used in the recurrent lumbar disc herniations (LDHs) and to share our experiences. Materials and Methods: Out of series of 1115 patients who underwent operations for LDH between 2006 and 2013, 70 patients underwent re-operations, which were included in this study. During surgery, lateral decompression performed over the medial facet joint to the superior facet joint border was seen after widening the laminectomy defect, and microdiscectomy was performed. The demographic findings of the patients, their complaints in admission to hospital, the level of operation, the condition of dural injury, the first admission in the prospective analysis, and their quality of life were evaluated through the Oswestry scoring during their postoperative 1st, 3rd, 6th-month and 1st, 3rd, 5th and 7th-year follow-up. In the statical analysis, Friedman test was performed for the comparison of the Oswestry scores and Siegel Castellan test was used for the paired nonparametrical data. A P < 0.05 was considered statistically significant. Results: Considering the Oswestry Index during the follow-ups, the values in the postoperative early period and follow-ups were seen to be significantly lower than those at the time of admission to hospital (P < 0.05). None of the patients, who re-operated by microdiscectomy, presented with iatrogenic instability in 7 years follow-up period. Conclusion: Microdiscectomy performed through a proper technique in the re-operation of recurrent disc herniations eases complaints and improves the quality of life. Long-term follow-ups are required for more accurate results.

scholarly journals Correlation of Disease Activity and Quality of Life of Patients with Psoriasis after Narrow-band Ultraviolet B Therapy

Folia Medica ◽  
2020 ◽  
Vol 62 (1) ◽  
pp. 89-93
Author(s):  
Lyubomir A. Dourmishev ◽  
Karolina Lyubomirova
Keyword(s):  
Quality Of Life ◽  
Narrow Band ◽  
Life Quality ◽  
Clinical Effectiveness ◽  
Symptom Assessment ◽  
Severity Index ◽  
Ultraviolet B ◽  
Effective Treatment Option ◽  
Pasi Score

Introduction: Treatment with ultraviolet light is a well-established and effective treatment option for mild to moderate psoriasis. The aims of the study were to measure the psoriasis area and severity index (PASI) reduction after narrow-band ultraviolet B (NB UVB) therapy, to evaluate the quality of life before and after treatment using the dermatology life quality index (DLQI), and to compare the clinical effectiveness with quality of life improvement. &nbsp; Material and methods: Twenty two patients (13 male and 9 female patients), aged between 21 to 70 years (mean age 40&plusmn;14.65 years) were enrolled in the study. NB UVB treatment was performed with 10 to 25 (mean 18.5; SD 3.39) procedures with cumulative doses of 5 to 19.4 J/cm2. The baseline median PASI score was 20.027 which decreased after therapy to 11.11. More than PASI 50% reduction was achieved in 40.91% of the patients after at least 6 weeks of treatment and the results are highly statistically significant. Quality of life (QoL) assessed using DLQI was found moderately affected by disease pretreatment. NB UVB therapy significantly increased DLQI score in spectrum of &lsquo;symptoms and feelings&rsquo; and &lsquo;treatment&rsquo;. &nbsp; Discussion: The PASI score reduction that we observed after NB-UVB therapy is consistent with the results reported by other authors. Baseline DLQI scores were indicative of moderate QoL impairments associated with disease. At the same time, the reduction of the DLQI index corresponding to improved QoL correlated with the objective clinical symptom assessment.&nbsp; &nbsp; Conclusion: Our data suggest that DLQI and PASI indexes are important complementary methods for comprehensive health assessment of patients with psoriasis.&nbsp;

scholarly journals An Observational Study to Evaluate Quality of Life in Patients with Melasma in A Tertiary Level Hospital of Pokhara

2021 ◽  
Vol 19 (1) ◽  
pp. 37-41
Author(s):  
Prajwal Pudasaini ◽  
Saraswoti Neupane
Keyword(s):  
Quality Of Life ◽  
Age Of Onset ◽  
Life Quality ◽  
Sun Exposure ◽  
Severity Index ◽  
Cross Sectional ◽  
Medical College ◽  
The Mean ◽  
Hormonal Therapies

Introduction: Melasma is an acquired hyper melanosis that becomes more pronounced after sun exposure. Centro facial which is the commonest pattern followed by Malar and Mandibular are three clinical patterns of Melasma. Genetic influences, exposure to UV radiation, pregnancy, hormonal therapies, contribute to the pathogenesis of melasma. Melasma may considerably have significant effect on quality of life of patients.   Objectives: The present study was conducted to evaluate the effects of melasma in quality of life (QoL) in the form of DLQI (Dermatology Life Quality Index) and severity of melasma according to Melasma Area and Severity Index (MASI).   Materials and Methods: This is a hospital based cross-sectional prospective study conducted in 193 Melasma patients in the Department of Dermatology, Venereology and Leprology, Gandaki Medical College and Teaching Hospital, Pokhara from November 2018 to November 2019. MASI score was calculated and the patients were provided with a Nepali version of DLQI to fill up.   Results: This study included 193 patients. Mean age of patients with melasma was 29.4 ± 8.5 years with maximum reported age of 59 years. The Mean age of onset of disease was 26.5 years. The Mean age of onset of disease had little impact on DLQI. The mean DLQI score was 10.9 ± 5.9, thus indicating “very large effect on patient’s life”. The mean MASI score was 6.6 ± 5.2. It was found that there was no correlation between severity of disease and DLQI scores (p=0.317) Conclusion: Melasma commonly affected females during second and third decades of life. It had a very large effect on patient’s life as assessed by DLQI.    

scholarly journals Dermatological life quality index in psoriasis

2019 ◽  
Vol 5 (4) ◽  
pp. 812
Author(s):  
N. R. Vignesh ◽  
Jayakar Thomas
Keyword(s):  
Quality Of Life ◽  
Quality Index ◽  
Tertiary Care ◽  
Life Quality ◽  
Inflammatory Disorder ◽  
Scalp Psoriasis ◽  
Patient Reported ◽  
Significant Impairment ◽  
Life Quality Index

<p class="abstract"><strong>Background:</strong> Psoriasis is an immune mediated chronic inflammatory disorder characterized by chronicity of the condition and periods of relapses and remissions. Dermatological life quality index (DLQI) is a widely used measure to determine the patient reported outcome in psoriasis. This study was conducted to evaluate the quality of life in psoriasis patients depending upon their age, sex, type of the disease, duration of the disease and with treatment.</p><p class="abstract"><strong>Methods:</strong> This is a cross sectional study performed in a tertiary care center in Chennai. The study was performed in 100 patients with a prepared DLQI questionnaire. The patients were asked to fill in the questionnaire and the results were graded from mild to very severe.<strong></strong></p><p class="abstract"><strong>Results:</strong> In this study, males outnumbered women in the ratio of 1.2:1. Patients in the age group 41-60 years formed the majority in this study. Itching and soreness of the lesions worsened the DLQI in majority of the patients. Quality of life of patients with psoriasis vulgaris was much affected when compared with other types of psoriasis like erythrodermic and scalp psoriasis. Also, married patients with psoriasis had significant impairment in their quality of life compared to unmarried patients.</p><p class="abstract"><strong>Conclusions:</strong> The findings of this study showed that psoriasis has a significant impairment in the quality of life and hence DLQI should be assessed at the first visit and also after treatment to improve the compliance of the patients towards the doctor as well as to the treatment.</p>

Comparison of the quality of life in patients with early and long-term rheumatoid arthritis (Preprint)

2020 ◽  
Author(s):  
Lyudmila Sizova
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Life Quality ◽  
Correct Choice ◽  
First Year ◽  
Early Ra ◽  
Sf 36 ◽  
State Medical Academy

BACKGROUND The research interest is the study of the quality of life of patients with rheumatoid arthritis of different duration. OBJECTIVE The aim of study was to compare the quality of life in patients with early rheumatoid arthritis (RA) against patients with long-term RA. METHODS The study included 164 participants: 114 outpatients with early RA, and 50 outpatients with long-term RA. Assessment of life quality in patients with RA detected impaired parameters of the HAQ, SF-36, QOL-RA Scale already during the first year of the disease. RESULTS The HAQ test found a comparable frequency of severe functional disorders in patients with early and long-term RA. According to the SF-36 questionnaire, patients with early RA suffered from physical pain than patients with long-term RA. The QOL-RA Scale demonstrated that patients in the early stages of the disease, the lowest scores for the "arthritis" and "joint pain", and participants with long-term RA for "health" also. CONCLUSIONS Results indicated that these questionnaires may be used for scientific purposes to identify the most susceptible parameters of the quality of life and to provide benefits for monitoring health status and correct choice of drugs. CLINICALTRIAL The Scientific Council of the Orenburg State Medical Academy (currently the University) approved research in 2005 year (Protocol No. 5). All patients gave their written consent to participate in the scientific study.

Sign in / Sign up

Export Citation Format

Share Document